# Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Central Nervous System Lymphoma

> **NCT00003632** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 30 (estimated)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** carmustine
- **DRUG:** cytarabine
- **DRUG:** etoposide
- **DRUG:** melphalan
- **DRUG:** methotrexate
- **PROCEDURE:** peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT00003632
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-09
- **Primary completion:** 2005-07
- **Final completion:** —
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2013-01-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003632, "Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Central Nervous System Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00003632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*